CompletedNot Applicable

Efficacy and Safety of Different Doses of Rituximab Therapy in Pemphigus Patients

China275 participantsStarted 2019-01-01

Plain-language summary

Investigating the clinical efficacy of different doses of rituximab in patients with pemphigus

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. patients with a diagnosis of pemphigus vulgaris or foliaceus in active stage based on guideline indicators, including typical clinical presentation, positive direct immunofluorescence microscopy findings, and/or detection of serum anti-Dsg3 and/or Dsg1 immunoglobin (Ig)G autoantibodies
✓. follow-up for at least 6 months after initiation of rituximab therapy

✕. Previous use of rituximab for other indications
✕. concomitant use of other biological agents within 6 months (e.g. Dupilumab,IL-17,FcRn)
✕. with a diagnosis of other variants of pemphigus besides PV and PF

relapse

Timeframe: week 4, 8, 12, 24, 36, 48 after treatment

disease control

Timeframe: week 4, 8, 12, 24, 36, 48 after treatment

adverse evert

Timeframe: week 4, 8, 12, 24, 36, 48 after treatment

NCT IDNCT07457944

SponsorRuijin Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-01-01